27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
- F-star Therapeutics Ltd (NASDAQ:FSTX) has entered into a license and collaboration agreement with Janssen Biotech Inc, a unit of Johnson & Johnson (NYSE:JNJ).
- Under the terms of the agreement, F-star will grant Janssen a worldwide, exclusive royalty-bearing license to research, develop, and commercialize up to five bispecific antibodies directed to Janssen therapeutic targets using F-star's Fcab and mAb2 platforms.
- Janssen will be responsible for all research, development, and commercialization activities under the agreement.
- Under the terms of the agreement, F-star is entitled to receive upfront fees of $17.5 million, near-term fees, and potential further milestones of up to $1.35 billion.
- F-star is also eligible to receive potential tiered mid-single digit royalties on annual net sales.
- Related: F-star's FS118 Development Program To Include Checkpoint Naïve Cancer Patients.
- Price Action: FSTX shares are up 9.53% at $7.01 during the premarket session on the last check Wednesday.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!